Newron Pharmaceuticals S.p.A. (SWX:NWRN)
14.72
-0.78 (-5.03%)
Last updated: Apr 2, 2026, 2:57 PM CET
Newron Pharmaceuticals Revenue
In the year 2025, Newron Pharmaceuticals had annual revenue of 19.13M EUR, down -62.78%. Newron Pharmaceuticals had revenue of 7.23M in the half year ending December 31, 2025, with 102.86% growth.
Revenue
19.13M EUR
Revenue Growth
-62.78%
P/S Ratio
18.10
Revenue / Employee
869.36K EUR
Employees
22
Market Cap
322.31M CHF
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.13M | -32.26M | -62.78% |
| Dec 31, 2024 | 51.39M | 42.33M | 467.41% |
| Dec 31, 2023 | 9.06M | 2.96M | 48.62% |
| Dec 31, 2022 | 6.09M | 332.00K | 5.76% |
| Dec 31, 2021 | 5.76M | 504.00K | 9.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Basilea Pharmaceutica AG | 232.38M |
| Idorsia | 220.58M |
| Santhera Pharmaceuticals Holding AG | 49.02M |
| BioVersys AG | 3.18M |
| Xlife Sciences AG | 839.38K |
| Molecular Partners AG | 681.00K |
| Addex Therapeutics | 158.54K |
Newron Pharmaceuticals News
- 9 days ago - Newron Presents 2025 Financial Results and Provides 2026 Outlook - Business Wire
- 13 days ago - Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS) - Business Wire
- 14 days ago - Newron Announces Agreement With the European Investment Bank (EIB) to Extend the Near-Term Tranche Repayment Dates of Its 2018 Finance Contract - Business Wire
- 15 days ago - Newron Announces Nominations to Its Board of Directors at Upcoming Annual General Meeting - Business Wire
- 6 weeks ago - Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program - Business Wire
- 2 months ago - Newron Notes Publication Highlighting Clinically Meaningful Benefits of Evenamide as an Adjunctive Treatment in Schizophrenia - Business Wire
- 3 months ago - EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan - Business Wire
- 3 months ago - Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent - Business Wire